$MRNA has 50-100% upside from $43 in FY 2025

$MRNA has 50-100% upside from $43 in FY 2025

- NASDAQ:MRNA had one of the worst year in 2024. However, cash position is underestimated and the market cap has gotten very low for a company which has proven it's excellence in manufacturing drug and research.


- NASDAQ:MRNA is working on cancer prevention vaccines which might get approvals in 2026 which will be a huge propeller for the stock long term.

- In the short term 2025, Bird flue and HMPV in China should push the stock higher to it's fair value around $65-90 range before end of the year.

- Wall street & Media pundits are saying nothing to worry about. But it's better to front run on these type of situations if you want to score big gains.

Read More

Share:

Latest News